Based on the INmune Bio Inc stock forecast from 5 analysts, the average analyst target price for INmune Bio Inc is USD 23.38 over the next 12 months. INmune Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of INmune Bio Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, INmune Bio Inc’s stock price was USD 8.04. INmune Bio Inc’s stock price has changed by +9.84% over the past week, -3.13% over the past month and -24.29% over the last year.
No recent analyst target price found for INmune Bio Inc
No recent average analyst rating found for INmune Bio Inc
Company Overview INmune Bio Inc
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Read Less
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and...Read More
Frequently Asked Questions About INmune Bio Inc (INMB) Stock
Based on ratings from 5 analysts INmune Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on INMB's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for INMB is USD 23.38 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 20.
Unfortunately we do not have enough data on INMB's stock to indicate if its overvalued.
The last closing price of INMB's stock was USD 8.04.
The most recent market capitalization for INMB is USD 0.17B.
Based on targets from 5 analysts, the average taret price for INMB is projected at USD 23.38 over the next 12 months.
This means that INMB's stock price may go up by +190.73% over the next 12 months.
We can't find any ETFs which contains INmune Bio Inc's stock.
As per our most recent records INmune Bio Inc has 13 Employees.
INmune Bio Inc's registered address is 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432.
You can get more information about it from INmune Bio Inc's website at https://www.inmunebio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About INmune Bio Inc (INMB) Stock
Based on ratings from 5 analysts INmune Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on INMB's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for INMB is USD 23.38 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 20.
Unfortunately we do not have enough data on INMB's stock to indicate if its overvalued.
The last closing price of INMB's stock was USD 8.04.
The most recent market capitalization for INMB is USD 0.17B.
Based on targets from 5 analysts, the average taret price for INMB is projected at USD 23.38 over the next 12 months.
This means that INMB's stock price may go up by +190.73% over the next 12 months.
We can't find any ETFs which contains INmune Bio Inc's stock.
As per our most recent records INmune Bio Inc has 13 Employees.
INmune Bio Inc's registered address is 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432.
You can get more information about it from INmune Bio Inc's website at https://www.inmunebio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INMB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
